Chemotherapy Can Complicate Immediate Breast Reconstruction After Mastectomy
New York, NY, December 3, 2014 /3BL Media/ – Immediate breast reconstruction following mastectomy is becoming more prevalent. However, in breast cancer patients undergoing simultaneous chemotherapy, thrombotic complications can arise that can delay or significantly modify reconstructive plans. Outcomes of cases illustrating potential complications are published in the current issue of Annals of Medicine and Surgery.
Chemotherapy is increasingly used to treat larger operable or advanced breast cancer prior to surgery. Chemotherapy delivered via the placement of a central venous line that remains in place for the duration of treatment can result in pre-operative thromboembolic events, which can require the administration of anticoagulation agents. This in turn can complicate subsequent surgery and is particularly significant when complex reconstruction is anticipated immediately following the mastectomy.
“There is limited research on the impact of this complication on breast reconstruction pathways and guidance for optimal management of these patients,” notes Professor Charles M. Malata, FRCS (Plast), who is Consultant Plastic & Reconstructive Surgeon at the Cambridge Breast Unit (Cambridge University Hospitals NHS Foundation Trust) and Professor of Academic Plastic Surgery at the Postgraduate Medical Institute of Anglia Ruskin University. “My colleagues and I present our clinical experience over four years of patients with breast cancer who developed thrombotic complications of their neoadjuvant chemotherapy venous lines prior to mastectomy and immediate breast reconstruction.”
Investigators analyzed the pathways of seven breast cancer patients who had received primary chemotherapy during which they experienced pre-operative line-related thrombosis requiring anticoagulant therapy. Five of these patients were able to undergo surgeries as planned, however in two instances this was not the case.
Detailing the thromboembolic complications and the consequences for reconstruction, the investigators report that for one patient, surgery was delayed for three weeks while the thrombosis was managed, followed by two separate surgeries over a 12-month period to fully accomplish the reconstruction. In the second case, the reconstruction was achieved as planned, but only after a three-month delay and required anticoagulation therapy and pre-operative radiotherapy.
According to Professor Malata, “As these cases demonstrate, line-associated thrombosis will be increasingly encountered by surgeons as more patients receive neoadjuvant chemotherapy and are managed by indwelling venous access devices. With multidisciplinary cooperation among surgeons, oncologists, and hematologists, the surgical management plan for these patients can remain largely unaffected.” He further cautions, “Reconstructive surgeons should, however, be flexible enough to alter their surgical plan in patients who develop line-related thrombosis.”
Notes for editors
“Pre-Operative Thrombotic Complications of Neoadjuvant Chemotherapy for Breast Cancer: Implications For Immediate Breast Reconstruction,” by Kate G Richards, MB BChir, MA; Parto Forouhi; Andrew Johnston; and Charles M Malata, BSc(HB), MB ChB, LRCP, MRCS, FRCS(Plast). DOI: http://dx.doi.org/10.1016/j.amsu.2014.11.001, Annals of Medicine and Surgery, Volume 3, Issue 4 (December 2014), published online in advance of issue by Elsevier.
This article is openly available at www.annalsjournal.com/article/S2049-0801(14)00067-3/fulltext. Journalists wishing to interview Dr. Malata may contact him directly at +44 771 289 7550 or email@example.com.
About Annals of Medicine and Surgery®
Annals of Medicine and Surgery (AMS) is an online-only, peer-reviewed, open access journal with a global outlook and focus on those training in medicine and surgery (postgraduate and undergraduate). AMS contains a rich mix of original clinical and basic science research, reviews, editorials, commentary, perspectives, debate, opinion, case reports, and journal club reports. Annals of Medicine and Surgery is owned by Surgical Associates Ltd. www.annalsjournal.com
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Allan Ross, Publisher
+1 212 633 3769